Effects of Vitamin D-Enriched Mushrooms on Vitamin D Status and Immune Function and Inflammatory Status in Adults
Effects of Vitamin D-Enriched Mushrooms on Vitamin D Status and Immune Function in Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Luz Componi
- Phone Number: 630-344-9402
- Email: lcomboni@purdue.edu
Study Contact Backup
- Name: Harrison Cottingham
- Phone Number: 812-606-2211
- Email: hcotting@purdue.edu
Study Locations
-
-
Indiana
-
West Lafayette, Indiana, United States, 47907
- Purdue University, Department of Nutrition Science
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI: 25.0-34.9 kg/m^2
- Total cholesterol <240 mg/dL
- low density lipoprotein cholesterol < 160 mg/dL
- triglycerides <300 mg/dL
- fasting glucose < 110 mg/dL
- systolic/diastolic blood pressure < 140/90 mmHg
- body weight stable for 3 months prior (+- 3 kg)
- stable physical activity regiment 3 months prior
- medication use stable for 6 months prior
- non-smoking
- non-diabetic
- not acutely ill
- females not pregnant or lactating
- willing to refrain from taking vitamin D supplements or any supplements containing vitamin D
- No history of bariatric surgery
- Not extremely or severely depressed (Beck's Depression Inventory Score <= 30)
- Agree not to donate blood for at least one month prior to, during, and for one month after the study
- Agree not to travel to sunny locations during the study period
- Agree to forgo any tanning bed or other tanning procedures during the study
- Willing and able to consume mushrooms and travel to testing facilities
Exclusion Criteria:
- Age <30 or >70
- BMI <25 or >35kg/m2
- Total cholesterol >240 mg/dL, low-density lipoprotein cholesterol >160 mg/dL, triglycerides >300mg/dL, fasting glucose >110 mg/dL
- Systolic/diastolic blood pressure >140/90 mm Hg
- Body weight changes in previous 3 months (±3 kg)
- Changes in physical activity regimen in the previous 3 months
- Medication changes in the previous 6 months
- Extremely or severely depressed (Beck's Depression Inventory Score >30)
- Unwilling to refrain from taking vitamin D supplements or any supplements containing vitamin D
- Regiment of megadosing vitamin D
- Unwilling to not to travel to sunny locations during the study period
- Unwilling to forgo any tanning bed or other tanning procedures during the study
- History of bariatric surgery
- Consuming a restricted diet (such as keto, gluten free, high protein, low carb, etc.)
- Smoking
- Diabetic
- Acute illness
- Females pregnant or lactating
- Unwilling to not to donate blood for at least one month prior to, during, and for one month after the study
- Allergic to mushrooms or bread
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mushrooms
Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily for 12 weeks.
|
Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
|
|
Placebo Comparator: No Mushrooms
This is a behavioral control where no change in Vitamin D status is expected to occur.
Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily for 12 weeks.
|
Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks.
Study powder is a commercially available carbohydrate.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in serum 25-hydroxy-vitamin D2 concentration
Time Frame: 12 weeks
|
25(OH) Vitamin D2/D3 by LC/MS
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in immunity/inflammation markers
Time Frame: 12 weeks
|
Immunoglobulin G, Immunoglobulin A, Immunoglobulin M (mg/dL)
|
12 weeks
|
|
Change in immunity/inflammation markers
Time Frame: 12 weeks
|
High Sensitivity C Reactive Protein (hs-CRP)
|
12 weeks
|
|
Change in immunity/inflammation markers
Time Frame: 12 weeks
|
Cytokine 13 Panel (pg/mL)
|
12 weeks
|
|
Change in bone remodeling
Time Frame: 12 weeks
|
Osteocalcin
|
12 weeks
|
|
Change in serum calcium concentrations
Time Frame: 12 weeks
|
Parathyroid hormone (PTH)
|
12 weeks
|
|
Change in perceived depression from baseline to mid to post-intervention
Time Frame: 12 weeks
|
Beck's Depression Inventory questionnaire
|
12 weeks
|
|
Change in perceived anxiety from baseline to mid to post-intervention
Time Frame: 12 weeks
|
Patient Health Questionnaire-9
|
12 weeks
|
|
Change in cognitive function from baseline to mid to post-intervention
Time Frame: 12 weeks
|
Repeatable Battery for the Assessment of Neuropsychological Status
|
12 weeks
|
|
Change in perceived daily mood from baseline to mid to post-intervention
Time Frame: 12 weeks
|
Profile of Mood States
|
12 weeks
|
|
Change in perceived quality of life from baseline to mid to post-intervention
Time Frame: 12 weeks
|
Medical Outcomes Study 36-Item Short Form Health Survey Version 2
|
12 weeks
|
|
Risk factors for cardiovascular disease
Time Frame: 12 weeks
|
Complete metabolic panel
|
12 weeks
|
|
Risk factors for cardiovascular disease
Time Frame: 12 weeks
|
Blood pressure
|
12 weeks
|
|
Risk factors for cardiovascular disease
Time Frame: 12 weeks
|
Lipoprotein Particle Plus (LPP+) Panel
|
12 weeks
|
|
Risk factors for cardiovascular disease
Time Frame: 12 weeks
|
Complete blood count (CBC)
|
12 weeks
|
|
Risk factors for type 2 diabetes
Time Frame: 12 weeks
|
Complete metabolic panel
|
12 weeks
|
|
Body weight
Time Frame: 12 weeks
|
Measures of weight (kg)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wayne Campbell, Purdue University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-2022-750
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.